Salt Lake City, UT — Lipocine Inc. announced positive progress in its pivotal phase 3 clinical trial evaluating oral brexanolone (LPCN 1154) for the treatment of postpartum depression (PPD). The…
Read More
Breaking developments in psychiatric research and updates from Psychopharmacology Bulletin.
Bristol Myers Squibb announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation to BMS-986446, a potential best-in-class anti–microtubule binding region tau (anti–MTBR-tau) antibody currently in…
Read More
What if the next leap in psychiatric treatment doesn’t come from tweaking dopamine or serotonin, but from reengineering the immune system, harnessing neuroplasticity, or refining orexin antagonism? In 2025, the…
Read More
By mid-2025, the psychopharmacology landscape feels paradoxical: on one hand, deeply familiar challenges — slow response, heterogeneity, side effects — still dominate clinical reality. On the other, a wave of…
Read More
What if the next leap in psychiatric therapeutics comes not from entirely new receptors, but from smarter targeting—or smarter delivery? From LSD-derived anxiety relief to once-weekly schizophrenia pills, this week’s…
Read More
Key Updates Biomarker-Stratified Antidepressant ResponseA randomized trial in JAMA Psychiatry (Sept 2025) found that patients with treatment-resistant depression who carried the ANK3 biomarker had improved outcomes with liafensine, suggesting potential…
Read More
From Psychedelics to Mechanism-Driven Precision: Recent Shifts in Depression Treatment What if we could reliably predict which antidepressant will work for a patient before waiting four weeks of trial-and-error? As…
Read More
Recent changes in the legal landscape in the United States have affected access to abortion, and this restricted access has profound effects on both physical and mental health of reproductive-aged…
Read More
The FDA’s Psychopharmacologic Drugs Advisory Committee is evaluating a New Drug Application (NDA) for a combination of brexpiprazole and sertraline as a potential treatment for posttraumatic stress disorder (PTSD). If…
Read More
Johnson & Johnson recently announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for lumateperone (Caplyta®), based on long-term data supporting…
Read More
